Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics, Inc. (LXEO) Liabilities and Shareholders Equity (2022 - 2023)

Lexeo Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $54.7 million for Q3 2023.

  • For Q3 2023, Liabilities and Shareholders Equity changed N/A year-over-year to $54.7 million; the TTM value through Dec 2023 reached $54.7 million, changed N/A, while the annual FY2022 figure was $97.1 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q3 2023 was $54.7 million at Lexeo Therapeutics, down from $97.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $97.1 million in Q4 2022 and bottomed at $54.7 million in Q3 2023.